IDH1 and acute myeloid leukemia: Following these results, ivosidenib (500 mg daily) and enasidenib (100 mg daily) both received FDA approval for adults with R/R IDH1- or IDH2-mutated AML, respectively, while only ivosidenib has been approved in newly diagnosed UNFIT patients.